Loading...

MedXY News - COPD

MedXY AI/MedXY News/Tag: COPD

MedXY News

EnglishTag

COPD

32 all articles · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial immunotherapy heart failure obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology public health critical care artificial intelligence breast cancer Alzheimer's disease diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

Mosaic Loss of Y Chromosome Links to Pulmonary Decline, Emphysema, and Accelerated Epigenetic Aging in Men: A Comprehensive Review

Mosaic Loss of Y Chromosome Links to Pulmonary Decline, Emphysema, and Accelerated Epigenetic Aging in Men: A Comprehensive Review

Mosaic loss of Y chromosome (mLOY) in men is strongly associated with diminished lung function, increased emphysema severity, and faster epigenetic aging, positioning mLOY as a novel biomarker for respiratory aging and COPD risk in males.

Section: Clinical UpdatesJul 15, 2026

Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value

Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value

A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.

Section: CardiologyJul 3, 2026

Empowering Climate-Conscious Inhaler Prescribing: A Patient-Physician Conversation Aid

Empowering Climate-Conscious Inhaler Prescribing: A Patient-Physician Conversation Aid

A novel conversation aid was developed and refined iteratively with patients and physicians to support shared decision-making for low carbon footprint inhaler prescribing in asthma and COPD, balancing environmental impact with safety and pa

Section: Family Medicine & NutritionJun 30, 2026

Mepolizumab and Blood Eosinophil Variability in COPD: A New Dimension in Targeted Therapy

Mepolizumab and Blood Eosinophil Variability in COPD: A New Dimension in Targeted Therapy

This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.

Section: newsJun 14, 2026

CT Small-Artery Loss Tracks Severe Pulmonary Hypertension in COPD and Fibrosing ILD More Closely Than Parenchymal Damage

CT Small-Artery Loss Tracks Severe Pulmonary Hypertension in COPD and Fibrosing ILD More Closely Than Parenchymal Damage

CT-derived pulmonary vascular metrics, especially the small-artery to total arterial volume ratio, identify severe pulmonary hypertension in chronic lung disease, with distinct vascular remodeling patterns in COPD and fibrosing ILD.

Section: newsJun 2, 2026

COPD Cuts Life Expectancy in a Severity-Dependent Manner, With Losses Comparable to or Greater Than Diabetes and Smoking

COPD Cuts Life Expectancy in a Severity-Dependent Manner, With Losses Comparable to or Greater Than Diabetes and Smoking

A large pooled US cohort study found that COPD substantially reduces life expectancy, even among never-smokers, with years of life lost increasing progressively from GOLD stage 1 through stage 4.

Section: newsMay 28, 2026

Motivational Interviewing and Air Cleaners for Smokers with COPD (MOVE): A Randomized, Double-Blind, Placebo-Controlled Trial

Motivational Interviewing and Air Cleaners for Smokers with COPD (MOVE): A Randomized, Double-Blind, Placebo-Controlled Trial

Portable HEPA air cleaners plus motivational interviewing improved symptoms and quality of life in smokers with COPD by reducing indoor particulate matter, though lung function and exacerbations did not significantly change.

Section: newsMay 27, 2026

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD

COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve su

Section: CardiologyMay 11, 2026

Mild and Single Moderate COPD Exacerbations Predict Future Risks: Insights from a Community-Based Cohort Study

Mild and Single Moderate COPD Exacerbations Predict Future Risks: Insights from a Community-Based Cohort Study

Community-based COPD patients with mild or single moderate exacerbations show higher future exacerbation risks and lung structural abnormalities, despite stable lung function decline rates.

Section: Internal MedicineApr 27, 2026

Once-Daily Umeclidinium-Vilanterol Outperforms Other LAMA-LABA Combinations in Reducing COPD Exacerbations

Once-Daily Umeclidinium-Vilanterol Outperforms Other LAMA-LABA Combinations in Reducing COPD Exacerbations

A large observational study finds that once-daily umeclidinium-vilanterol dry powder inhaler significantly reduces COPD exacerbation risk compared to glycopyrrolate-formoterol and tiotropium-olodaterol, while maintaining similar safety prof

Section: newsApr 13, 2026

Predicting the Tumble: Recurrent Fall History and Dual-Task Impairment Emerge as Primary Risk Factors in COPD

Predicting the Tumble: Recurrent Fall History and Dual-Task Impairment Emerge as Primary Risk Factors in COPD

A new clinical prediction model identifies prior recurrent falls, multimorbidity, and impaired dual-task mobility as key predictors of future falls in patients with COPD, offering a new tool for targeted geriatric intervention in respirator

Section: Internal MedicineFeb 23, 2026

Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk

Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk

Recent evidence reveals that COPD in adults under 50 is more prevalent than previously thought, significantly increasing the risk of premature death and heart failure. Furthermore, impaired lung function trajectories starting in childhood p

Section: Internal MedicineJan 1, 2026

Smartphone-Based Pulmonary Rehabilitation Bridging the Gap in Chronic Respiratory Care: A Randomized Controlled and Feasibility Study

Smartphone-Based Pulmonary Rehabilitation Bridging the Gap in Chronic Respiratory Care: A Randomized Controlled and Feasibility Study

A randomized trial demonstrates that a smartphone app-based pulmonary rehabilitation program significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable alternative to trad

Section: Family Medicine & NutritionDec 23, 2025

Bridging the Care Gap: Smartphone-Based Pulmonary Rehabilitation Enhances Quality of Life and Physical Activity in Chronic Respiratory Disease

Bridging the Care Gap: Smartphone-Based Pulmonary Rehabilitation Enhances Quality of Life and Physical Activity in Chronic Respiratory Disease

A 12-week randomized controlled trial reveals that smartphone-based pulmonary rehabilitation significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable and feasible altern

Section: Internal MedicineDec 23, 2025

Bridging the Gap after Pulmonary Rehabilitation: Evaluating the PICk UP Programme in COPD Management

Bridging the Gap after Pulmonary Rehabilitation: Evaluating the PICk UP Programme in COPD Management

A randomized trial shows that a six-month personalised community-based physical activity programme sustains physical activity improvements and functional performance post-pulmonary rehabilitation in COPD patients, though other health benefi

Section: Rehabilitation MedicineOct 24, 2025

Optimizing Exercise Progression in COPD with Chronic Respiratory Failure: Insights from a Pilot Trial of High Intensity Interval Training

Optimizing Exercise Progression in COPD with Chronic Respiratory Failure: Insights from a Pilot Trial of High Intensity Interval Training

This pilot randomized trial investigates the safety, feasibility, and efficacy of high intensity interval training modalities compared to constant-load endurance training in COPD patients with chronic respiratory failure, revealing promisin

Section: Rehabilitation MedicineOct 24, 2025

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.

Section: newsOct 9, 2025

Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial

Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial

Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.

Section: newsOct 9, 2025

High-Flow Nasal Oxygen Reduces Hypoxaemia During Bronchoscopy in COPD: Insights from the PROSA 2 Randomised Trial

High-Flow Nasal Oxygen Reduces Hypoxaemia During Bronchoscopy in COPD: Insights from the PROSA 2 Randomised Trial

The PROSA 2 trial demonstrates that high-flow nasal oxygen significantly reduces hypoxaemia time and events compared to conventional low-flow oxygen in COPD patients undergoing bronchoscopy, improving procedural safety without compromising

Section: newsOct 9, 2025

Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness

Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness

This study elucidates that airway eosinophilia in COPD is linked to enhanced type 2 inflammation in airway epithelium and predicts responsiveness to inhaled corticosteroids, revealing a distinct COPD endotype with potential for precision th

Section: newsOct 9, 2025